Respiratory Tract Infection Treatment Market Analysis | CMI - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Respiratory Tract Infection Treatment Market Analysis | CMI

Description:

Read here the latest updates on the Respiratory Tract Infection Treatment Market Analysis published by CMI team – PowerPoint PPT presentation

Number of Views:5

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Respiratory Tract Infection Treatment Market Analysis | CMI


1
  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

2
RESPIRATORY TRACT INFECTION TREATMENT MARKET
ANALYSIS
  • Respiratory Tract Infection Treatment Market, by
    Drug Class (Antibiotics, Non-Steroidal
    Anti-Inflammatory Drug (NSAIDS), Cough
    Suppressant, Nasal Decongestant, and Others), by
    Disease Indication (Upper Respiratory Tract
    Infection and Lower Respiratory Tract Infection),
    by Distribution Channel (Hospital Pharmacies,
    Retail Pharmacies, and Online Pharmacies), and by
    Region (North America, Latin America, Europe,
    Asia Pacific, Middle East, and Africa) - Size,
    Share, trends, and Forecast to 2026
  • The global respiratory tract infection treatment
    market was valued at US 35.64 Bn in 2017, and is
    expected to witness a CAGR of 6.5 over the
    forecast period (2018 2026).

3
Figure 1. Global Respiratory Tract Infection
Treatment Market Share Analysis (), By Product
Type
4
Market Drivers
  • Increasing prevalence of respiratory diseases is
    expected to drive growth of the Respiratory Tract
    Infection Treatment Market
  • Increasing prevalence of chronic respiratory
    diseases such as asthma, chronic pulmonary lung
    disease, pulmonary hypertension, and occupational
    lung disease are the major factors augmenting
    growth of the respiratory tract infection market.
  • For instance, according to the Biomed Central
    Respiratory Research 2016, asthma and chronic
    obstructive pulmonary disease (COPD) are common
    chronic obstructive lung disorders characterized
    by variable airflow limitation and airway hyper
    responsiveness, affecting over 25 million people
    in the U.S.

5
  • Various organizations, institutions, and agencies
    are working towards improving the diagnosis and
    medical care needed to reduce the global burden
    of respiratory diseases. For instance, the Global
    Alliance against Chronic Respiratory Diseases
    (GARD) was formed with the support from the World
    Health Organization (WHO) to control chronic
    respiratory diseases. The main objective of GARD
    is to develop simple and affordable strategies
    for chronic respiratory diseases (CRD) and to
    encourage economies to implement health promotion
    and CRD prevention policies.
  • Presence of various drugs in pipeline, which is
    expected to be launched over the forecast period
    will also boost the market growth of respiratory
    tract infection treatment. Some of the drugs in
    the pipeline include Relenza (GSK), MK7264 (Merck
    Co.), Presatovir (Gilead), AZD7594, and PT010
    (AstraZeneca).

6
Market Restraints
  • However, presence of various generic
    manufacturers and low cost of various drugs
    including antibiotics in the market may hinder
    the respiratory tract infection treatment market
    to some extent during the forecast period.

7
Respiratory Tract Infection Treatment Market-
Regional Analysis
  • On the basis of region, the global respiratory
    tract infection treatment market is segmented
    into North America, Latin America, Europe, Asia
    Pacific, Middle East, and Africa.
  • North America is expected to hold a dominant
    position in the global respiratory tract
    infection treatment market over the forecast
    period, owing to increasing number of
    hospitalizations and emergency visits associated
    with acute or life threatening medical problems.
  • According to the study by Society of Critical
    Care Medicine 2016, over 5.7 million patients are
    admitted annually in intensive care units (ICUs)
    in the U.S. for support of airway, breathing or
    circulation, and comprehensive management of
    injury.

8
  • Also, according to the Centers for Disease
    Control and Prevention (CDC), 2017, around 1.7
    million emergency department visits with chronic
    and unspecified bronchitis were registered in the
    U.S. hospital facilities.
  • Furthermore, several pharmaceutical and
    biotechnological companies are focusing on
    expanding their business in Asia Pacific region,
    to maximize their RD activities, as this region
    provides better access to patients for clinical
    trials, with low cost operational efficiencies.
    Increasing government investments in research and
    development, patient awareness, improved health
    care infrastructure and facilities, high
    disposable income, and prevalence of unhealthy
    lifestyle are also expected to foster growth of
    the respiratory tract infection treatment market
    in the Asia Pacific region.

9
Figure 2 Global Respiratory Tract Infection
Treatment Market Share (), By Region
10
Key Development
  • Increasing approval of new drugs by the Food and
    Drug Administration (FDA) is also expected to
    propel the overall market growth over the
    forecast period. For instance, in November 2017,
    the U.S. FDA approved Fasenra (Benralizumab)
    manufactured by AstraZeneca, a respiratory
    biologic for patients aged 12 years and older who
    are suffering from asthma, and with an
    eosinophilic phenotype.

11
Key Players
  • Key players operating in the global respiratory
    tract infection treatment market include Abbott
    Laboratories, AstraZeneca, Plc, Abbvie Inc.,
    Boehringer Ingelheim GmbH, Cipla Pharmaceutical
    Company, GlaxoSmithKline plc, Pfizer Inc., Merck
    Co., Novartis AG, F. Hoffman La Roche Ltd,
    Sanofi, and Teva Pharmaceutical Industries Ltd.

12
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Reference https//www.coherentmarketinsights.com
    /market-insight/respiratory-tract-infection-treatm
    ent-market-2030

13
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

14
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
    U.S.
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

15
  • Thank You!
  • Kindly follow CMI Social Media Profiles
    for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com